RCK and Alcohol/Food Interactions
There are 5 alcohol/food/lifestyle interactions with RCK (clonidine / ketorolac / ropivacaine).
Caffeine ROPivacaine
Minor Drug Interaction
Information for this minor interaction is available on the professional version.
cloNIDine Alcohol (Ethanol)
Moderate Drug Interaction
CloNIDine and ethanol may have additive effects in lowering your blood pressure. You may experience headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate. These side effects are most likely to be seen at the beginning of treatment, following a dose increase, or when treatment is restarted after an interruption. Let your doctor know if you develop these symptoms and they do not go away after a few days or they become troublesome. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
ketorolac Alcohol (Ethanol)
Moderate Drug Interaction
Ask your doctor before using ketorolac together with ethanol. Do not drink alcohol while taking ketorolac. Alcohol can increase your risk of stomach bleeding caused by ketorolac. Call your doctor at once if you have symptoms of bleeding in your stomach or intestines. This includes black, bloody, or tarry stools, or coughing up blood or vomit that looks like coffee grounds. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
High Blood Pressure (Hypertension)
Major Potential Hazard, Moderate plausibility
NSAIDs - fluid retention
Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs). Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure. Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.
References
- "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn PROD (2002):
- "Product Information. Nalfon (fenoprofen)." Xspire Pharma PROD (2002):
- "Product Information. Indocin (indomethacin)." Merck & Co., Inc PROD (2002):
- "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories PROD (2002):
- "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc PROD (2002):
- "Product Information. Anaprox (naproxen)." Roche Laboratories PROD (2006):
- "Product Information. Clinoril (sulindac)." Merck & Co., Inc PROD (2001):
- "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical PROD (2001):
- "Product Information. Relafen (nabumetone)." SmithKline Beecham PROD (2001):
- "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals PROD (2001):
- "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn PROD (2001):
- "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories PROD (2001):
- "Product Information. Daypro (oxaprozin)." Searle PROD (2001):
- "Product Information. Mobic (meloxicam)." Boehringer-Ingelheim PROD (2001):
High Blood Pressure (Hypertension)
Moderate Potential Hazard, Moderate plausibility
NSAIDs - hypertension
Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events. NSAIDs should be used with caution in patients with hypertension. Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.
References
- "Product Information. Indocin (indomethacin)." Merck & Co., Inc PROD (2002):
- "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc PROD (2002):
- "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals PROD (2001):
- "Product Information. Relafen (nabumetone)." SmithKline Beecham PROD (2001):
- "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals PROD (2001):
- "Product Information. Dolobid (diflunisal)." Merck & Co., Inc PROD (2001):
- "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn PROD (2001):
- "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories PROD (2001):
- "Product Information. Daypro (oxaprozin)." Searle PROD (2001):
- "Product Information. Celebrex (celecoxib)." Searle PROD (2001):
- "Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc (2012):
- "Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD) (2016):
RCK drug interactions
There are 845 drug interactions with RCK (clonidine / ketorolac / ropivacaine).
RCK disease interactions
There are 18 disease interactions with RCK (clonidine / ketorolac / ropivacaine) which include:
- GI toxicity
- platelet aggregation inhibition
- renal dysfunction
- asthma
- fluid retention
- GI toxicity
- rash
- thrombosis
- bradyarrhythmia
- depression
- hypotension
- renal dysfunction
- sedatives/alcohol
- anemia
- heart failure
- hepatotoxicity
- hyperkalemia
- hypertension
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.